NewsRoom Articles

Lexaria, a global innovator in drug delivery platforms, announced the appointment of Richard Christopher as its new CEO, replacing Chris…

Lexaria, a global innovator in drug delivery platforms, is reporting on its eight-week body weight results from its WEIGHT-A24-1 ongoing…

Lexaria, a global innovator in drug delivery platforms, has just announced its 4-week and 8-week blood glucose results from its…

INM-901 oral formulation shows encouraging results in preclinical studies High bioavailability of INM-901 oral formulation was shown to provide similar…

Lexaria, a global innovator in drug delivery platforms, just reported positive results from its applied research program conducted in collaboration…

A long-term preclinical study of Alzheimer's Disease (“AD”) drug candidate INM-901 included four groups: untreated disease-free, INM-901-treated disease-free, placebo-treated Alzheimer's…

Lexaria, a global innovator in drug delivery platforms, is exploring its patented DehydraTECH(TM) technology for the oral delivery of glucagon-like…

The company provided updates for its study programs for 2024, with a focus on its glucagon-like peptide-1 (“GLP-1”) agonist research…

Lexaria, a global innovator in drug delivery platforms, is exploring alternatives to traditional diabetes and obesity management through its patented…

The report explores the growth, competition, and consumer trends, for lesser known cannabinoids The report highlights a 5.4% revenue increase…